BHVN · Insider Trading
Biohaven Ltd.
Every open-market purchase and sale reported by BHVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Kimberly Gentile | SVP, Clinical Operations | A | +1,000 deriv. | — |
| 2026-03-19 | Kishan Mehta | Director | G | — | — |
| 2026-03-09 | John W Childs | Director | Buy | +28,400 | +$864.12K |
| 2026-03-03 | Kimberly Gentile | SVP, Clinical Operations | A | +175,000 deriv. | — |
| 2026-03-03 | Matthew Buten | Chief Financial Officer | A | +175,000 deriv. | — |
| 2026-03-03 | George C. Clark | VP, Chief Accounting Officer | A | +50,000 deriv. | — |
| 2026-03-03 | Vlad Coric | Chief Executive Officer | A | +550,000 deriv. | — |
| 2026-03-03 | Bruce Car | Chief Scientific Officer | A | +175,000 deriv. | — |
| 2026-01-07 | Kimberly Gentile | SVP, Clinical Operations | MIXED | +1,794 | −$19.42K |
| 2026-01-07 | Vlad Coric | Chief Executive Officer | MIXED | +6,820 | −$73.78K |
| 2026-01-07 | George C. Clark | VP, Chief Accounting Officer | MIXED | +1,383 | −$11.09K |
| 2026-01-07 | Matthew Buten | Chief Financial Officer | MIXED | +1,656 | −$25.76K |
| 2026-01-07 | Bruce Car | Chief Scientific Officer | MIXED | +2,369 | −$23.64K |
| 2025-11-18 | George C. Clark | VP, Chief Accounting Officer | Buy | +17,000 | +$144.77K |
| 2025-11-17 | John W Childs | Director | Buy | +3,333,333 | +$25.00M |
| 2025-11-17 | Vlad Coric | Chief Executive Officer | Buy | +666,666 | +$5.00M |
| 2025-11-17 | Gregory Bailey | Director | Buy | +400,000 | +$3.00M |
| 2025-05-07 | Irina Antonijevic | Director | A | +31,716 deriv. | — |
| 2025-05-07 | Julia P Gregory | Director | A | +31,716 deriv. | — |
| 2025-05-07 | Gregory Bailey | Director | A | +31,716 deriv. | — |
| 2025-05-07 | Robert J Hugin | Director | A | +31,716 deriv. | — |
| 2025-05-07 | Kishan Mehta | Director | A | +31,716 deriv. | — |
| 2025-05-07 | John W Childs | Director | A | +31,716 deriv. | — |
| 2025-05-07 | Michael Thomas Heffernan | Director | A | +31,716 deriv. | — |
| 2025-03-05 | John W Childs | Director | Buy | +73,170 | +$3.00M |
| 2025-03-05 | John W Childs | Director | Buy | +32,700 | +$996.24K |
| 2025-01-07 | Kimberly Gentile | SVP, Clinical Operations | MIXED | +1,794 | −$75.58K |
| 2025-01-07 | Matthew Buten | Chief Financial Officer | MIXED | +1,689 | −$98.96K |
| 2025-01-07 | Bruce Car | Chief Scientific Officer | MIXED | +2,419 | −$90.07K |
| 2025-01-07 | George C. Clark | VP, Chief Accounting Officer | MIXED | +1,383 | −$43.16K |
| 2025-01-07 | Vlad Coric | Chief Executive Officer | MIXED | +7,445 | −$262.95K |
| 2024-12-31 | John W Childs | Director | Buy | +29,000 | +$1.04M |
| 2024-10-03 | Vlad Coric | Chief Executive Officer | Buy | +21,052 | +$999.97K |
| 2024-10-03 | John W Childs | Director | Buy | +21,052 | +$999.97K |
| 2024-09-25 | Gregory Bailey | Director | Buy | +5,000 | +$220.97K |
| 2024-07-19 | John W Childs | Director | Buy | +28,400 | +$1.01M |
| 2024-06-20 | Bruce Car | Chief Scientific Officer | Buy | +30,000 | +$1.01M |
| 2024-05-31 | John W Childs | Director | Buy | +28,000 | +$996.24K |
| 2024-05-15 | Gregory Bailey | Director | Buy | +15,000 | +$512.88K |
| 2024-05-14 | John W Childs | Director | Buy | +28,500 | +$1.00M |
| 2024-05-02 | Gregory Bailey | Director | A | +16,592 deriv. | — |
| 2024-05-02 | Irina Antonijevic | Director | A | +16,592 deriv. | — |
| 2024-05-02 | Robert J Hugin | Director | A | +16,592 deriv. | — |
| 2024-05-02 | Julia P Gregory | Director | A | +16,592 deriv. | — |
| 2024-05-02 | John W Childs | Director | A | +16,592 deriv. | — |
| 2024-05-02 | Michael Thomas Heffernan | Director | A | +16,592 deriv. | — |
| 2024-05-02 | Kishan Mehta | Director | A | +16,592 deriv. | — |
| 2024-04-25 | Gregory Bailey | Director | Buy | +25,503 | +$999.17K |
| 2024-04-23 | Gregory Bailey | Director | Buy | +48,780 | +$2.00M |
| 2024-04-23 | Vlad Coric | Chief Executive Officer | Buy | +121,951 | +$5.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John W Childs | Director | 8,015,222 | $86.40M |
| Vlad Coric | Chief Executive Officer | 3,006,673 | $32.41M |
| Gregory Bailey | Director | 2,020,071 | $21.78M |
| Matthew Buten | Chief Financial Officer | 198,246 | $2.14M |
| Kimberly Gentile | SVP, Clinical Operations | 101,513 | $1.09M |
| George C. Clark | VP, Chief Accounting Officer | 86,978 | $937.62K |
| Bruce Car | Chief Scientific Officer | 40,096 | $432.23K |
| Julia P Gregory | Director | 25,665 | $276.67K |
| Kishan Mehta | Director | 22,662 | $244.30K |
| Michael Thomas Heffernan | Director | 15,178 | $163.62K |
| Irina Antonijevic | Director | 13,535 | $145.91K |
| Robert J Hugin | Director | 12,959 | $139.70K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BHVN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.